Although the antiangiogenic activity of type I interferons (IFN) is well known, the mechanism by which it occurs is unclear. In the present study, we have investigated effects of short-term and long-term IFN-a exposure on different types of endothelial cells (EC). Short-term IFN-a treatment resulted in a distinct reduction of apoptosis of serum and growth factor starved HUVEC and HDMEC. This was accompanied by a strong upregulation of the IFN inducible guanylate binding protein-1 (GBP-1) whereas no consistent regulation of several known antiapoptotic proteins was evident. Stable transfection of HUVEC with an expression vector for GBP-1 mimicked the protective effect of IFN-a, suggesting that GBP-1 may contribute to the inhibition of apoptosis. When IFN-a, together with serum and EC growth factors, was present continuously a decrease of population doublings by more than 40% was observed in both HDMEC and HCAEC. In addition, the cells displayed a senescent phenotype significantly earlier than control cells and showed an increased adherence for monocytes. Our findings suggest that the antiangiogenic effect of IFN-a is mediated by inducing EC senescence rather than EC apoptosis. Furthermore IFN-a released in chronic inflammatory conditions might contribute via its prosenescent activity to the pathogenesis of atherosclerosis.
Type I interferons (IFNs) are immunomodulatory cytokines that are upregulated during viral infections. 1 In contrast to IFN-b which is a single protein produced by lymphocytes, 1 IFN-a comprises about 20 structurally related proteins which are primarily produced by monocytes 1 and plasmacytoid dendritic cell (PDC) precursors. 2 However, during viral and chlamydial infection or after stimulation with immunomodulators, 3 type I IFNs are also produced by a variety of other cell types including EC, 4 smooth muscle cells 5 and keratinocytes. 6 IFN-a inhibits viral replication and supports virus clearance in infected cells in an autocrine and paracrine fashion. Therapeutically, IFN-a is used in the treatment of Hepatitis C 7 and in antitumor therapy, 8, 9 and for its antiangiogenic activity in the treatment of recalcitrant hemangiomas. 10 Besides in clinical practice, the antiangiogenic effect of IFN-a has been well established in animal models: high-dose and long-term treatment inhibits neoangiogenesis of solid tumors 11, 12 and retards wound healing. 13 This antiangiogenic action of type I IFNs is thought to be primarily due to their antiproliferative activity on EC. [14] [15] [16] [17] However, the antiproliferative activity of IFNs is not generally accepted and is challenged by data of several investigators. [18] [19] [20] Some authors have even reported an increased proliferation of microvascular EC after IFN-a 2a treatment. 14, 20, 21 Another explanation for the antiangiogenic activity of IFNs was suggested by Sgonc et al, 22 who reported that IFN-a may induce apoptosis of EC. However, confirmation of these data by others is still pending.
These contradictory data prompted us to study the effects of short-term and long-term IFN-a treatment on different types of EC in vitro. We demonstrate that short-term IFN-a treatment under conditions of serum starvation inhibits EC apoptosis whereas long-term treatment of cells in the presence of growth factors and serum induces a sencescent phenotype. As these senescent EC also showed an increased adherence of blood mononuclear cells our data suggest that continuous exposure to IFN-a, as it occurs in chronic inflammatory disorders, might be one of the factors able to trigger and/or aggravate atherosclerosis.
Methods

Cell Culture and Reagents
Human umbilical vein (HUVEC) endothelial cells were isolated and characterized as described previously 23 and human dermal microvascular (HDMEC) and human coronary arterial (HCAEC) endothelial cells were purchased from CellSystems (St Katharinen, Germany). Stable transduction of HUVEC with GBP-1 was reported previously. 24 HUVEC of the same passage transduced with an empty control vector served as a negative control. All cells were serially cultured on gelatine-coated plastic culture dishes in endothelial cell growth medium (EGM) or endothelial cell growth medium EBM-2 including endothelial cell growth serum (CellSystems). All experiments with EC were initiated between passages 4 and 8. Experiments were performed in either M199 medium, 23 basal medium lacking both serum and growth factors (short-term exposure, antiapoptotic experiments) or in fully supplemented medium (long-term exposure, senescence experiments) with either INTRON s -A (Interferon a-2b, Schering, Kenilworth, NY, USA) or ROFERON s -A (Interferon a-2a, Hoffmann-La Roche Inc, Nutley, NJ, USA) at the concentrations indicated.
Population doublings were counted as described. 25 Apoptosis of EC was assessed by typical morphological changes observed by inverted light microscopy as well as by using a cell death detection ELISA measuring histone released in the supernatant (Roche, Mannheim, Germany). Ki-67 (clone MIB-1, Dako, Glostrup, Denmark) and podoplanin 26 expression were evaluated on EC grown on Lab-Tek Chamber Slides (Nalge Nunc, Naperville, IL, USA) by immunohistochemistry. b-Galactosidase staining of EC grown on Lab-Tek Chamber Slides was performed as described by Dimri et al.
27
Western Blotting Subconfluent endothelial cell monolayers were incubated in the presence or absence of IFN-a for 20-50 min for AKT phosphorylation experiments and 18-24 h for all other experiments. At the end of the incubation, cells were harvested and lysed in NP-40 buffer (1% NP-40 in PBS) containing 1 mM PMSF and 100 mM sodium orthovanadate (Sigma). Protein concentrations were measured by a Micro BCA Protein Assay Reagent (Pierce, Rockford, IL, USA). Lysates were subjected to SDS-PAGE in 12% gels. Prior to SDS-PAGE, lysates were mixed with reducing SDS-loading buffer (7.2% SDS, 9 mmol/l EDTA, 20% glycerol, 10 mmol/l dithiothreitol, 13 mmol/l Tris-phosphate buffer, pH 6.8) and boiled for 5 min. Separated proteins were then electroblotted onto a nitrocellulose membrane (Schleicher & Schü ll, Germany) at 0.8 mA/cm 2 for 2 h. The membranes containing the complete set of samples were blocked in blocking buffer (5% nonfat dry milk in PBS) followed by immune overlay with the following antibodies: RIG-G (clone 25, BD Biosciences, Heidelberg, Germany), p21 (Ab-1, Oncogene, Cambridge, MA, USA), p27 (clone SX53G8, Dako, Glostrup, Denmark), p53 (Immunotech, Marseille, France), Cyclin D1 (Ventana, Tucson, AZ, USA), Bak (TC-100, Calbiochem, Cambridge, MA, USA), Mcl-1 (Dako), Bcl-2 (bcl-2-124, Dako), bax (Ab-1, Calbiochem) and bcl-x (Transduction Laboratories, Lexington, KY, USA), Id-1 (Santa Cruz Biotechnology, Santa Cruz, CA, USA), polyclonal rabbit 24 or monoclonal rat anti-GBP-1 (1B1 28 ), AKT (Cell Signalling, Beverly, MA, USA) and pAKT (Ser473, Cell Signalling). After washing, bound antibodies were detected with HRP-labelled sheep anti mouse-IgG (Amersham Life Science, UK) or HRP-labelled goat anti-rabbit IgG (Pierce, Rockford, IL, USA), respectively. After rinsing in Western blotting detection reagent ECL (Amersham), membranes were exposed to a X-OMAT-AR film (Eastman Kodak, NY, USA) for 5, 30 and 60 min each. Western blot bands of Id-1 and GBP-1 were quantitated by GelPro Analyzer 4.0 (Media cybernetics).
Isolation of Monocytes from PBMNC
Peripheral blood mononuclear cells (PBMNC) were prepared from peripheral venous blood of healthy volunteers after anticoagulation with 1.8 mg. EDTA/ ml blood. After Ficoll-Paque (Pharmacia, Uppsala, Sweden) density gradient centrifugation, PBMNC were collected and washed three times with HBSS (Gibco, Invitrogen Corporation, Carlsbad, CA, USA). Positive selection of monocytes was performed by adding MACS colloidal super-paramagnetic microbeads conjugated with anti-human CD14 antibodies (Miltenyi Biotec, Bergisch Gladbach, Germany) to cooled, freshly prepared PBMNC preparations in MACS buffer (PBS (Gibco, Invitrogen Corporation, Carlsbad, CA, USA) with 5 mM EDTA and 0.5% bovine serum albumin (SigmaAldrich, St Louis, MO, USA)) according to the manufacturer's instructions. Cells and microbeads were incubated for 15 min at 4-61C. In the mean-time, the separation column (Miltenyi Biotec) was positioned in the magnetic cell separator MidiMACS and washed with MACS buffer at room temperature. The cells were washed with MACS buffer, resuspended, and loaded onto the top of the separation column. The eluent containing CD14 À cells was discarded and after removal of the column from the magnet, trapped monocytes (CD14 þ ) were eluted with cold MACS buffer, centrifuged, counted and resuspended at a concentration of 1 Â 10 7 cells in 1 ml HBSS. Cells were loaded with 10 mM/ml carboxyfluorescein diacetate (CFDA, Molecular Probes, Eugene, OR, USA) for 15 min at 371C, washed, centrifuged and finally resuspended at a concentration of 2 Â 10 6 cells/ml endothelial cell medium (EBM-2).
Cell Adhesion Experiments
HCAEC (CellSystems) and HDMEC of different population doublings were seeded on coverslips placed in tissue culture plates (Falcont, Becton Dickinson Labware, Franklin Lakes, NJ, USA) and grown to confluence. Monolayers were washed twice with EBM-2 and incubated with 500 000 CFDA loaded monocytes/cm 2 for 2 h at 371C, 5% CO 2 . The plates were shaken every 15 min. After the incubation period, monolayers were washed three times with EBM-2 to remove nonadherent monocytes and fixed with 4% paraformaldehyde. Coverslips were mounted on glass slides using fluorescent mounting medium (Fluoprep, bioMérieux, Marcyl'Etoile, France) and analyzed on a conventional fluorescent microscope (Olympus Provis, Vienna, Austria).
Statistical Analysis
The statistical significance of intergroup differences was evaluated by univariate analysis of variance (ANOVA) and subsequent Tukey-tests. As a control, Wilcoxon tests were performed as appropriate for additional comparison of groups. A two-tailed Pvalue of r0.05 was considered statistically significant. SPSS 10.0.7 (SPSS Inc., Chicago, IL, USA) was used for analysis.
Data are presented as the mean value7s.e. for each group.
Results
Type I Interferon Enhances Survival of HUVEC and HDMEC after Growth Factor Withdrawal
To test the effects of IFN-a on EC survival and proliferation in vitro, we exposed HUVEC and HDMEC to 1000 IU/ml IFN-a in the presence and absence of serum and EC growth factors. As expected and reported previously 29 . No significant effect of IFN-a on cell numbers and cell survival was observed when EC were grown in medium supplemented with EC growth factors (data not shown). These data demonstrate that IFN-a treatment prevents EC apoptosis after serum and growth factor withdrawal but does not induce EC proliferation in vitro at the concentrations used.
Interferon-a Downregulates Id-1 and Upregulates GBP-1 Expression in EC
To investigate whether expression of proteins involved in cell survival was modulated, we tested EC lysates after IFN-a exposure by Western blot analysis. As a positive control for IFN-a-activity, the expression of the IFN-a-inducible protein RIG-G was analyzed. RIG-G was consistently and strongly induced in both HUVEC and HDMEC by IFN-a ( Figure 3 ). By contrast, no significant differences were found in the expression of cell cycle regulatory proteins. In HUVEC p21, p27, p53 and Cyclin D1 were slightly downregulated ( Figure 3 ), whereas no effect at all was observed in HDMEC. Of the antiapoptotic proteins investigated only Mcl-1 was very slightly upregulated in HUVEC and HDMEC (Figure 3 ), whereas Bcl-2 and Bcl-x expression showed no consistent regulation in different experiments (not shown). Bak was slightly upregulated in most experiments in HDMEC but not HUVEC ( Figure 3 ). Significant results were obtained with the inhibitor of differentiation Id-1, a protein associated with proliferation and negatively correlated to senescence and differentiation, 30 and GBP-1, an inhibitor of proliferation. 24 In both HUVEC and HDMEC Id-1 was consistently downregulated by IFN-a, whereas GBP-1 was distinctly upregulated (Figure 3 ). These data demonstrate that IFN-a did not lead to a dramatic alteration of the expression of pro-or antiapoptotic proteins in EC. The fact that GBP-1 was upregulated and Id-1 was downregulated is consistent with the finding above that IFN-a did not induce proliferation of serum-starved cells.
As IFN-a has been reported to activate the PI3K/ AKT pathway, 31 which is implicated in prevention of apoptosis, 32 we tested EC lysates for phophorylation of AKT. No increase of AKT phosphorylation in HDMEC ( Figure 4 ) was detected in six independent experiments 15, 30 and 50 min after IFN-a stimulation, demonstrating that the PI3K/Akt pathway is not involved in the antiapoptotic effect of IFN-a. were grown to confluence in normal EC growth medium. Four days after switch of cultures to basal medium without growth factor and serum supplements, the vast majority of cells detached from the bottom of the culture vessels and showed morphological signs of apoptosis (c, d). Apoptosis was largely prevented when basal medium had been supplemented with IFN-a at 1000 U/ml (e, f).
Effect of IFN
Overexpression of GBP-1 Protects HUVEC from Serum-Deprivation-Induced Apoptosis
As GBP-1 was the only protein investigated that apart, from RIG-G, was reproducibly and distinctly regulated by IFN-a in both HUVEC and HDMEC, we tested its potential role for cell survival. Overexpression of GBP-1 in HUVEC resulted in a significant decrease in apoptosis after serum and growth factor deprivation ( Figure 5 ). Protection against apoptosis was comparable to that of IFN-a treatment and could only be marginally augmented by the addition of IFN-a ( Figure 5 ), indicating that the antiapoptotic effect of this cytokine is at least partly mediated by GBP-1. The effect of GBP-1 on survival of HUVEC was also evident when the number of surviving cells was compared at different time points after seeding ( Figure 6 ).
Continuous Exposure to Interferon-a Reduces Population Doublings and Induces a Senescent Phenotype in HDMEC and HCAEC
The antiapoptotic effect we observed with shortterm exposure of EC to IFN-a may be interpreted as y HUVEC (n ¼ 6, ÀECGM) d4: Po0.028 for Int A and Rof (Wilcoxon).
& HDMEC (n ¼ 6, ÀECGM) d1: Po0.0001 for Int A and Rof, d2: Po0.023 for Int A, d4: Po0.0001 for Int A and Po0.002 for Rof (Tukey-HSD).
% HDMEC (n ¼ 6, ÀECGM) d1: Po0.028 for Int A and Rof, d2: Po0.025 for Int A, d4: Po0.012 for Int A and Po0.025 for Rof (Wilcoxon). (b) IFN-a treatment leads to increased EC survival after serum and growth factor withdrawal. EC survival was quantified by counting EC at different time points after serum and growth factor withdrawal. Stimulation of HUVEC and HDMEC with both Intron A and Roferon resulted in significantly higher cell numbers after 2 and 4 days when compared to untreated cells. The number of unstimulated cells was set as 100%, data are presented as mean value7s.e. Western blot analyses were performed on whole cell lysates and repeated at least five times. RIG-G was strongly upregulated by IFN-a in all experiments and served as a positive control for IFN-a activity. In HUVEC a weak downregulation of p21, p27, p53 and Cyclin D1 by IFN-a was observed, which was not found in HDMEC. In both cell types a slight downregulation of Id-1 and a strong upregualtion of GBP-1 was regularly detected.
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To mimic more closely an in vivo situation as it occurs in chronic inflammation where IFN-a is constantly present, we investigated the effects of continuous exposure to this cytokine.
When IFN-a was added every 2 days to fully supplemented culture medium of HDMEC and HCAEC, no distinct and reproducible morphologic differences were observed between treated and untreated cultures during the first few passages. However, after 2-4 weeks in medium supplemented with IFN-a, both HDMEC and HCAEC flattened, became irregular in shape with an increased diameter, thus exhibiting a phenotype characteristic for senescent EC (Figure 7a and b) . The induction of cellular senescence by IFN-a was further confirmed Figure 4 IFN-a treatment of HDMEC does not induce AKT phosphorylation. HDMEC grown in serum-free medium for 24 h were either exposed to 10% fetal bovine serum (FBS) or 1000 U/ ml IFN-a (Intron A). Western blot analysis with a monoclonal antibody recognizing phosphorylation of AKT at Ser473 15 min after stimulation revealed that serum, but not IFN-a, was able to induce AKT phosphorylation (upper panel). Total amount of AKT was equal in stimulated and control samples (lower panel). (Figure 7d ) as compared to the untreated cultures (Figure 7c ). Podoplanin, a marker of lymphatic endothelial cells 26 was detectable only on singly dispersed cells whereas the bulk of EC remained FVIII positive (not shown), confirming that no selection for non-blood vascular EC occurred during prolonged in vitro culture. On further culture, IFN-a-treated cells stopped growing altogether, leading to a dramatically reduced number of population doublings in HDMEC and HCAEC (Figure 8) . A reduction of population doublings was also observed in HUVEC, however, it did not reach statistical significance (Figure 8 ). In one of seven experiments using HCAEC, spindle-shaped EC derived from a culture of senescent IFN-a-treated cells started to proliferate and eventually replaced the senescent cells. In this case, the final number of population doublings was higher in the stimulated cell cultures in contrast to all other experiments (not shown). When we analyzed the expression of Id-1 and GBP-1 proteins in long-term IFN-a-treated EC, we found no regulation of the former, whereas a distinct upregulation of GBP-1 was consistently observed at all time points tested ( Figure 9) .
A typical functional feature of senescent EC is the enhanced binding of monocytes. 33 When HDMEC or HCAEC were stimulated with IFN-a for 24 or 48 h no increased binding of freshly isolated human monocytes was observed when compared with untreated EC (not shown). When IFN-a treatment was continued for more than 10 population doublings, HCAEC showed a senescent phenotype and monocyte-adherence was distinctly increased in nine of 10 separate experiments (Figure 10 ). The same was observed in three of four experiments with senescent HDMEC (not shown). These data confirm that prolonged IFN-a treatment induces a premature senescent phenotype in blood vascular EC. As shortterm treatment of EC with IFN-a did not result in an increase of monocyte binding in accordance Figure 7 Continuous addition of IFN-a leads to premature senescence of EC. When IFN-a was added every second day to the EC cultures, HDMEC became enlarged, flattened and irregularly shaped corresponding to a senescent phenotype (b, passage 7) at passage numbers when cells grown without IFN-a were still inconspicuous (a, passage 7). As further indication of premature senescence of HDMEC after IFN-a treatement they showed a strongly increased expression of b-galactosidase (d, passage 14) as compared to control cells (c, passage 14). 34, 16 this binding effect is not caused by the direct cytokine-induced upregulation of adhesion molecules, but by their dysregulation due to senescence. 33 
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Discussion
The antiangiogenic activities of IFN-a have been well documented in both animal models and clinical trials. Here, we studied the short-term and long-term effects of this cytokine on different types of EC in vitro. We found that short-term exposure to this cytokine prevents EC apoptosis after growth factor withdrawal and that long-term exposure induces replicative senescence in EC.
Our findings that IFN-a neither significantly inhibits nor induces growth of EC and does not only not induce apoptosis but rather acts antiapoptotically for EC contradicts previous studies which reported antiproliferative [14] [15] [16] [17] or promitotic, 14, 20, 21 as well as proapoptotic 22 activities. Unfortunately a direct comparison of our results with the ones of these studies is difficult if not impossible, since the experimental conditions were either vaguely described 14, 22 or altogether different. 20, 21 Antiapoptotic activities of IFN-a in other cell types have been observed and related to activation of the PI-3 Kinase/AKT pathway. 31 In our experimental setting, a participation of this pathway could be excluded since (1) no phosphorylation of AKT was observed after IFN-treatment, and (2) apoptosis of EC due to 24 which was consistently also upregulated under our experimental conditions, protected HUVEC against apoptosis comparably to IFN-a treatment. GBP-1 is a member of the family of large GTPases and has been shown to mediate the antiangiogenic effects of inflammatory cytokines on EC by inhibiting bFGF-and VEGF-induced proliferation and MMP-1 expression in EC. 24, 35 However, these activities cannot explain the GBP-1 antiapoptotic effect in serum-starved cells, where proliferation rates and MMP-1 expression are low. Of note, GBP-1 is a high turnover GTPase and continuous expression of this protein may induce a considerable shift of the cellular GTP pool. This may lead to a metabolically repressed EC phenotype, which may be less prone to stress-induced apoptosis by growth factor deprivation. Reduced cell reactivity of GBP-1 expressing cells to paracrine stimulation is in agreement with a less prominent increase of free intracellular calcium concentrations, which has been observed in constitutively GBP-1 expressing HUVEC after treatment with bFGF and VEGF (Sturzl, Pogoda, unpublished observations).
When IFN-a was added continuously to the cultures of HDMEC and HCAEC we observed a strong reduction of the number of their population doublings that is in agreement with the antiproliferative activity of GBP-1. By contrast, this effect was somehow lower in HUVEC again demonstrating differences in the biological responses of different EC types. 36 Along with the reduction in population doubling, HDMEC and HCAEC acquired a phenotype characteristic for senescent EC, that is they became enlarged and started to express b-galactosidase more strongly and in a significantly higher proportion of cells than untreated populations. In contrast to EC exposed to IFN-a for a short time, these long-term treated cells also showed an increased adhesiveness for blood-derived monocytes.
For example, telomerase reverse transcriptase (hTERT) has been reported to be downregulated by IFN-a in T-cells and leukemic cell lines 37 and IFI 16, a prosenescent scaffold protein necessary for the assembly of transcription factor compexes, 38 is upregulated in fibroblasts 39 and prostatic cell lines. 38 Further studies will be necessary to exclude or confirm the involvement of these proteins in IFNa induced senescense of EC. As in short-term exposure, long-term exposure to IFN-a also resulted in strong expression of GBP-1. We have followed the GBP-1-transduced HUVEC and HUVEC transduced with a control vector for over four passages (cells stopped growing then) without observing a difference in their morphology, suggesting that this enzyme might not be causally involved in this process (data not shown).
It might well be that the chronic administration of IFN-a for the treatment of hemangiomas or solid tumors induces senescence in EC in vivo analogous to our in vitro findings, and might thus contribute to its antiangiogenetic effects. 10, 11 Furthermore, premature endothelial senescence represents a critical step in the development of vasculopathies, 40, 41 for example, by decreasing proliferative capacity and increasing rates of apoptosis of aged endothelial cells and thereby contributing to functional impairment of the endothelial monolayer. 42, 43 If chronic production of IFN-a from endogenous sources plays a similar role in vivo as in vitro it might be one of the factors contributing to the induction or aggravation of atherosclerosis. It has been amply documented that atherosclerosis does not merely result from the accumulation of lipids due to hyperlipidemia but is associated with a variety of predisposing factors independent of lipid metabolism. 44 Chronic inflammation, either locally or systemically, promotes the formation of atherosclerotic lesions. [45] [46] [47] Inflammatory reactions which have been shown to increase the risk for atherosclerosis range from autoimmune diseases such as systemic vasculitides 48 to microbial infections including cytomegalovirus (CMV), 45 herpes simplex virus-1 (HSV-1), hepatitis A virus, 49 Epstein-Barr virus (EBV), 50 Chlamydia pneumoniae and Helicobacter pylori. 46, 47 These inflammatory reactions may occur at sites distant to those where atherosclerotic lesions form. 46 IFN-a is strongly produced in several of these diseases 4, [51] [52] [53] and it is tempting to speculate that IFN-a-induced EC senescence and resulting leucocyte adhesiveness could trigger or promote atherosclerotic lesions in the vessel walls. An additional argument for the involvement of IFN-a in pathogenesis of atherosclerotic is provided by recent work on LDL receptor-deficient mice in which chronic administration of IFN-a leads to the development of atherosclosis. 54 The mode of action in this work has been explained by induction of hyperlipidemia. However, it is conceivable that a direct effect on EC might also have been operant in this system.
In conclusion, we have found that short-term exposure to IFN-a protects different types of EC against apoptosis and that the induction of GBP-1 is an important part of this protective effect. Chronic administration of this cytokine induces premature senescence and leukocyte adhesiveness of EC, a mechanism by which IFN-a might participate in the pathogenesis of atherosclerosis. punktprogramm) and the interdisciplinary Center for Clinical Research (IZKF, projects A1 and B11) of the University of Erlangen to MS.
